ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.83M | 2.04M | 2.31M | 1.52M | 2.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.27M | 2.75M | 2.83M | 1.78M | 2.90M |
| Operating Income | -2.27M | -2.75M | -2.83M | -1.78M | -2.90M |
| Income Before Tax | -2.40M | -2.75M | -2.83M | -13.93M | -2.90M |
| Income Tax Expenses | -- | 9.70K | -- | -596.10K | -500.00 |
| Earnings from Continuing Operations | -2.40M | -2.76M | -2.83M | -13.34M | -2.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.40M | -2.76M | -2.83M | -13.34M | -2.90M |
| EBIT | -2.27M | -2.75M | -2.83M | -1.78M | -2.90M |
| EBITDA | -2.27M | -2.75M | -2.82M | -1.77M | -2.90M |
| EPS Basic | -2.43 | -3.31 | -4.53 | -59.63 | -30.18 |
| Normalized Basic EPS | -1.52 | -2.06 | -2.83 | -4.96 | -18.66 |
| EPS Diluted | -2.43 | -3.31 | -4.53 | -59.63 | -30.18 |
| Normalized Diluted EPS | -1.52 | -2.06 | -2.83 | -4.96 | -18.66 |
| Average Basic Shares Outstanding | 988.40K | 834.90K | 623.60K | 223.70K | 97.30K |
| Average Diluted Shares Outstanding | 988.40K | 834.90K | 623.60K | 223.70K | 97.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
